Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews
Contextual factors that influence the need for RWE are similar between regulatory and HTA decision-making, with variations seen in questions addressable with RWE.
Authors
- Rolf H. H. Groenwold (ORCID: https://orcid.org/0000-0001-9238-6999)
- Lotty Hooft (ORCID: https://orcid.org/0000-0002-7950-2980)
- Olaf M. Dekkers (ORCID: https://orcid.org/0000-0002-1333-7580)
- Helga Gardarsdóttir (ORCID: https://orcid.org/0000-0001-5623-9684)
- Anthonius de Boer (ORCID: https://orcid.org/0000-0002-9485-8037)
- Saskia le Cessie (ORCID: https://orcid.org/0000-0003-2154-4923)
- Marieke S. Jansen (ORCID: https://orcid.org/0000-0001-5669-2593)
Institutions
- University of Iceland (IS)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Pharmo Institute (NL)
- Medicines Evaluation Board (NL)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/pds.70074
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26